Syndax Announces Participation in March Investor Conferences
Rhea-AI Summary
Syndax (Nasdaq: SNDX) announced management will participate in three investor conferences in March 2026, including TD Cowen, Leerink Global Healthcare, and Barclays Global Healthcare. CEO Michael A. Metzger will take part in fireside chats on March 2, 11, and 12, 2026.
A live webcast and limited-time replay will be available in the company’s Investor section at www.syndax.com.
Positive
- None.
Negative
- None.
News Market Reaction – SNDX
In the Feb 23 session, SNDX gained 1.07%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Earnings call date | Neutral | +1.6% | Announced Q4 and full-year 2025 results date and investor call details. |
| Feb 05 | Conference participation | Neutral | -1.4% | CEO fireside chat at Guggenheim Emerging Outlook: Biotech Summit with webcast. |
| Feb 04 | Inducement equity grants | Negative | -3.9% | Announced 11,600-share option grants to new employees under inducement plan. |
| Jan 12 | Prelim 2025 results | Positive | -1.3% | Reported strong preliminary Revuforj and Niktimvo revenues and cash position. |
| Jan 07 | Access program launch | Positive | +8.7% | Launched multi-regional Revuforj managed access program outside the U.S. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News flow has been frequent, with generally mild price responses; one positive access/expansion update saw the strongest upside reaction.
Over the past two months, Syndax has issued several operational and investor‑relations updates. These include an earnings call announcement on Feb 26, 2026, multiple conference participation notices, inducement equity grants, preliminary 2025 revenue and cash figures highlighted on Jan 12, 2026, and a multi‑regional Revuforj access program announced on Jan 7, 2026. Price reactions were usually modest, except for the Revuforj access news, which produced an 8.7% gain, indicating strongest enthusiasm for concrete commercial or access milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- TD Cowen 46th Annual Health Care Conference in Boston, MA, with a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET.
- Leerink Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Wednesday, March 11, 2026, at 1:40 p.m. ET.
- Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, with a fireside chat on Thursday, March 12, 2026, at 11:00 a.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
